Các biến thể PAI-1 điều chỉnh các kiểu hình liên quan đến hội chứng chuyển hóa ở quần thể người da trắng béo phì và tiểu đường

Reaven GM (1988) Role of insulin resistance in human disease. Diabetes 37:1595–1607 DeFronzo RA, Ferrannini E (1991) Insulin resistance. A multifaceted syndrome responsible for niddm, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173–194 Juhan-Vague I, Thompson SG, Jespersen J (1993) Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT angina pectoris study group. Arterioscler Thromb 13:1865–1873 Hamsten A, Faire U de, Walldius G et al. (1987) Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 2:3–9 Kruithof EK, Tran-Thang C, Ransijn A, Bachmann F (1984) Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 64:907–913 Juhan-Vague I, Alessi MC (1997) PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 78:656–660 Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I (1997) Production of plasminogen activator inhibitor 1 by human adipose tissue: Possible link between visceral fat accumulation and vascular disease. Diabetes 46:860–867 Loskutoff DJ, Samad F (1998) The adipocyte and hemostatic balance in obesity: Studies of PAI-1. Arterioscler Thromb Vasc Biol 18:1–6 Shimomura I, Funahashi T, Takahashi M et al. (1996) Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity. Nat Med 2:800–803 Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D (1988) Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemost 60:491–494 Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J (1990) Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 10:1067–1073 Nordt TK, Klassen KJ, Schneider DJ, Sobel BE (1993) Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb 13:1822–1828 Klinger KW, Winqvist R, Riccio A et al. (1987) Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis. Proc Natl Acad Sci USA 84:8548–8552 Arya R, Blangero J, Williams K et al. (2002) Factors of insulin resistance syndrome-related phenotypes are linked to genetic locations on chromosomes 6 and 7 in nondiabetic mexican-americans. Diabetes 51:841–847 Duggirala R, Blangero J, Almasy L et al. (2000) A major susceptibility locus influencing plasma triglyceride concentrations is located on chromosome 15q in mexican americans. Am J Hum Genet 66:1237–1245 Landin K, Tengborn L, Smith U (1990) Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 227:273–278 Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P (1989) Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients-relationship with plasma insulin. Thromb Haemost 61:370–373 Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE (1993) The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 42:945–949 Vague P, Juhan-Vague I, Aillaud MF et al. (1986) Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 35:250–253 Landin K, Stigendal L, Eriksson E et al. (1990) Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 39:1044–1048 Schafer K, Fujisawa K, Konstantinides S, Loskutoff DJ (2001) Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J 15:1840–1842 Boutin P, Wahl C, Samson C, Vasseur F, Laget F, Froguel P (2000) Big dye terminator cycle sequencing chemistry: accuracy of the dilution process and application for screening mutations in the TCF1 and GCK genes. Hum Mutat 15:201–203 Blomeke B, Sieben S, Spotter D, Landt O, Merk HF (1999) Identification of N-acetyltransferase 2 genotypes by continuous monitoring of fluorogenic hybridization probes. Anal Biochem 275:93–97 Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM (1993) The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 268:10739–10745 Eriksson P, Kallin B, van 't Hooft FM, Bavenholm P, Hamsten A (1995) Allele-specific increase in basal transcription of the plasminogen- activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 92:1851–1855 Grubic N, Stegnar M, Peternel P, Kaider A, Binder BR (1996) A novel g/a and the 4 g/5 g polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. Thromb Res 84:431–443 Pannekoek H, Veerman H, Lambers Het al. (1986) Endothelial plasminogen activator inhibitor (PAI): a new member of the serpin gene family. EMBO J 5:2539–2544 Deleage G, Roux B (1987) An algorithm for protein secondary structure prediction based on class prediction. Protein Eng 1:289–294 Kyte J, Doolittle RF (1982) A simple method for displaying the hydropathic character of a protein. J Mol Biol 157:105–132 Cambien F, Poirier O, Lecerf L et al. (1992) Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359:641–644 Tiret L, Kee F, Poirier O et al. (1993) Deletion polymorphism in angiotensin-converting enzyme gene associated with parental history of myocardial infarction. Lancet 341:991–992 Schachter F, Faure-Delanef L, Guenot F et al. (1994) Genetic associations with human longevity at the APOE and ACE loci. Nat Genet 6:29–32 Woods D, Hickman M, Jamshidi Y et al. (2001) Elite swimmers and the D allele of the ACE I/D polymorphism. Hum Genet 108:230–232 Nazarov IB, Woods DR, Montgomery HE et al. (2001) The angiotensin converting enzyme I/D polymorphism in russian athletes. Eur J Hum Genet 9:797–801 Mansfield MW, Stickland MH, Grant PJ (1995) Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 74:1032–1034 Nagi DK, McCormack LJ, Mohamed-Ali V, Yudkin JS, Knowler WC, Grant PJ (1997) Diabetic retinopathy, promoter (4 g/5 g) polymorphism of PAI-1 gene, and PAI-1 activity in Pima indians with type 2 diabetes. Diabetes Care 20:1304–1309 Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS (1995) Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 44:37–42 Mansfield MW, Stickland MH, Grant PJ (1995) Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 74:842–847 McCormack LJ, Nagi DK, Stickland MH et al. (1996) Promoter (4 g/5 g) plasminogen activator inhibitor-1 genotype in Pima indians: Relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome. Diabetologia 39:1512–1518 Viitanen L, Pihlajamaki J, Halonen P et al. (2001) Association of angiotensin converting enzyme and plasminogen activator inhibitor-1 promoter gene polymorphisms with features of the insulin resistance syndrome in patients with premature coronary heart disease. Atherosclerosis 157:57–64 Hoffstedt J, Andersson IL, Persson L, Isaksson B, Arner P (2002) The common −675 4 g/5 g polymorphism in the plasminogen activator inhibitor −1 gene is strongly associated with obesity. Diabetologia 45:584–587 Henry M, Chomiki N, Scarabin PY et al. (1997) Five frequent polymorphisms of the PAI-1 gene: Lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arterioscler Thromb Vasc Biol 17:851–858 Freeman MS, Mansfield MW (2002) Comment to: J. Hoffstedt et al. (2002) the common −675 4 g/5 g polymorphism in the plasminogen activator inhbitor-1 gene is strongly associated with obesity. Diabetologia 45:1602–1603 Abramowicz MJ, Duprez L, Parma J, Vassart G, Heinrichs C (1997) Familial congenital hypothyroidism due to inactivating mutation of the thyrotropin receptor causing profound hypoplasia of the thyroid gland. J Clin Invest 99:3018–3024